FDA — authorised 22 August 1962
- Application: NDA050051
- Marketing authorisation holder: WYETH AYERST
- Local brand name: GRISACTIN
- Indication: CAPSULE — ORAL
- Status: approved
🇺🇸 GRIFULVIN V in United States
FDA authorised GRIFULVIN V on 22 August 1962
Marketing authorisations
FDA — authorised 14 July 1971
- Application: ANDA060618
- Marketing authorisation holder: J AND J
- Local brand name: GRIFULVIN V
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 May 1972
- Application: NDA050448
- Marketing authorisation holder: JOHNSON AND JOHNSON
- Local brand name: GRIFULVIN V
- Indication: SUSPENSION — ORAL
- Status: approved
FDA — authorised 20 June 1972
- Application: ANDA060212
- Marketing authorisation holder: WYETH AYERST
- Local brand name: GRISACTIN
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 June 1980
- Application: ANDA062279
- Marketing authorisation holder: VALEANT LUXEMBOURG
- Local brand name: GRIFULVIN V
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 26 January 1984
- Application: ANDA062483
- Marketing authorisation holder: VALEANT LUXEMBOURG
- Local brand name: GRIFULVIN V
- Indication: SUSPENSION — ORAL
- Status: approved
FDA
- Status: approved
Other Dermatology approved in United States
Frequently asked questions
Is GRIFULVIN V approved in United States?
Yes. FDA authorised it on 22 August 1962; FDA authorised it on 14 July 1971; FDA authorised it on 30 May 1972.
Who is the marketing authorisation holder for GRIFULVIN V in United States?
WYETH AYERST holds the US marketing authorisation.